Back to top

Image: Bigstock

Summit Stock Falls on FDA Rejection for Lung Cancer Drug

Read MoreHide Full Article

Key Takeaways

  • Summit received an FDA CRL for ivonescimab plus chemotherapy in certain NSCLC patients.
  • The HARMONi trial met its PFS endpoint but failed to show a statistically significant OS benefit.
  • The CRL delays ivonescimab's potential U.S. launch, commercial revenues and Summit's first marketed product.

Summit Therapeutics (SMMT - Free Report) announced that the FDA has issued a complete response letter (CRL) regarding its biologics license application (BLA) seeking approval for ivonescimab plus chemotherapy in certain patients with non-small cell lung cancer (NSCLC).

Following the announcement, SMMT shares lost 20% in pre-market trading. The FDA's decision represents a major regulatory setback for Summit, as approval of ivonescimab could have marked the company's entry into the U.S. commercial market with its first marketed product.

Year to date, shares of SMMT have lost 19.1% compared with the industry’s 0.4% decline.

Zacks Investment Research
Image Source: Zacks Investment Research

Why FDA Issued CRL to SMMT’s Ivonescimab

The FDA has issued a CRL, declining to approve the application in its current form due to insufficient evidence of effectiveness. Earlier this year, Summit submitted the BLA for ivonescimab in combination with platinum-based chemotherapy for patients with locally advanced or metastatic NSCLC who have previously received epidermal growth factor receptor tyrosine kinase inhibitor therapy. Subsequently, the FDA accepted the application for review, with a regulatory decision initially expected this month.

The application was supported by May 2025 results from the phase III HARMONi study, which evaluated the combination against chemotherapy alone in the targeted NSCLC population. The study met one of its two primary endpoints, demonstrating a statistically significant improvement in progression-free survival (PFS) but failed to meet its other endpoint of overall survival (OS). However, the combination showed a favorable trend toward improved OS.

In July 2026, a subsequent post-hoc analysis of longer-term follow-up data reported an OS hazard ratio of 0.76 across the overall study population, as well as the Asian and Western patient subgroups. While the longer-term data indicated a favorable survival trend, they did not overcome the lack of a statistically significant OS benefit in the pivotal study which appears to have been a key obstacle to approval. Despite the significant PFS benefit, the FDA determined that the available evidence was insufficient to establish a favorable benefit-risk profile for the combination in this indication.

The CRL delays ivonescimab's potential U.S. launch, pushing back revenue prospects and creating uncertainty around its regulatory pathway. Investors will watch for Summit's next steps, including FDA discussions, additional data requirements and the timeline for a potential resubmission.

SMMT’s Zacks Rank & Stocks to Consider

Summit currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the biotech sector are Amneal Pharmaceuticals (AMRX - Free Report) ,AC Immune (ACIU - Free Report) and Adaptive Biotechnologies (ADPT - Free Report) , carrying a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.

Over the past 30 days, earnings per share estimates for Amneal Pharmaceuticals have increased from $1.03 to $1.06 for 2026. Over the same period, estimates for 2027 earnings per share have risen from $1.16 to $1.21. AMRX’s shares have surged 69.7% year to date.

Amneal Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 27.21%.

Over the past 30 days, loss per share estimates for AC Immune have narrowed from 60 cents to 54 cents for 2026. Over the same period, estimates for 2027 earnings per share have increased from 17 cents to 43 cents. ACIU’s shares have declined 32.2% year to date.

AC Immune’s earnings beat estimates in each of the trailing four quarters, with an average surprise of 37.79%.

Over the past 30 days, loss per share estimates for Adaptive Biotechnologies have narrowed from 55 cents to 39 cents for 2026. Over the same period, estimates for 2027 loss per share have also improved from 17 cents to 3 cents. ADPT’s shares have surged 78.8% year to date.

Adaptive Biotechnologies’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 53.62%.

Published in